An updated systematic review and meta-analysis of the use of octreotide for the prevention of postoperative complications after pancreatic resection

Hao Zheng, MD, Jiwei Qin, MD, PhD, Ning Wang, MD, Wanjing Chen, MD, Qiang Huang, MD, PhD*

Abstract

Background: The use of octreotide prophylaxis following pancreatic surgery is controversial. We aimed to evaluate the effectiveness of octreotide for the prevention of postoperative complications after pancreatic surgery through this systematic review and meta-analysis.

Methods: Literature databases (including the MEDLINE, EMBASE, and Cochrane databases) were searched systematically for relevant articles. Only randomized controlled trials (RCTs) were eligible for inclusion in our research. We extracted the basic information regarding the patients, intervention procedures, and all complications after pancreatic surgery and then performed the meta-analysis.

Results: Thirteen RCTs involving 2006 patients were identified. There were no differences between the octreotide group and the placebo group with regard to pancreatic fistulas (PFs) (relative risk [RR] = 0.79, 95% confidence interval [CI] = 0.62–0.99, P = .05), clinically significant PFs (RR = 1.01, 95% CI = 0.68–1.50, P = .95), mortality (RR = 1.21, 95% CI = 0.78–1.88, P = .40), biliary leakage (RR 0.84, 95% CI = 0.39–1.82, P = .66), delayed gastric emptying (RR = 0.83, 95% CI = 0.54–1.27, P = .39), abdominal infection (RR = 1.00, 95% CI = 0.66–1.52, P = 1.00), bleeding (RR = 1.16, 95% CI = 0.78–1.72, P = .46), pulmonary complications (RR = 0.73, 95% CI = 0.45–1.18, P = .20), overall complications (RR = 0.80, 95% CI = 0.64–1.01, P = .06), and reoperation rates (RR = 1.18, 95% CI = 0.77–1.81, P = .45). In the high-risk group, octreotide was no more effective at reducing PF formation than placebo (RR = 0.81, 95% CI = 0.67–1.00, P = .65). In addition, octreotide had no influence on the incidence of PF (RR = 0.38, 95% CI = 0.14–1.05, P = .06) after distal pancreatic resection and local pancreatic resection.

Conclusion: The present best evidence suggests that prophylactic use of octreotide has no effect on reducing complications after pancreatic resection.

Abbreviations: CI = confidence interval, DP = distal pancreatectomy, ISGPF = International Study Group for Pancreatic Surgery, MD = mean difference, PD = pancreaticoduodenectomy, PFs = pancreatic fistulas, POPF = postoperative pancreatic fistula, PPPD = pylorus-preserving pancreaticoduodenectomy, RCTs = randomized controlled trials, RR = relative risk, RRs = risk ratios, SMD = standardized mean difference.

Keywords: meta-analysis, octreotide, pancreatic fistula, pancreatic resection

1. Introduction

Surgery involving the pancreas is performed to treat pancreatic, bile duct, and periampullary malignant diseases, chronic pancreatitis, trauma, and so on. The incidence of complications after pancreatic surgery remains as high as 28% to 58%[1–3] despite constant exploration and striving to improve surgical techniques and intensive care. Pancreatic fistula (PF) and other complications caused by postoperative PF (POPF) are the most important complications after pancreatic surgery and may even lead to death. Various methods have been tried to reduce the incidence of POPF; however, the incidence of PF is not significantly lower than previously.[4–6] Surgeons are constantly exploring different surgical procedures and using different anastomosis instruments and different medicines to prevent complications. One of the most common methods used is prophylactic somatostatin or synthetic somatostatin analogues to decrease the incidence of PF by inhibiting the exocrine secretions of the pancreas.[7–9]

Octreotide is a synthetic octapeptide analogue of endogenous somatostatin with more specific, more potent,
and longer-acting inhibitory effects.\textsuperscript{[10–12]} Although many clinical trials have evaluated the function of octreotide to decrease complications after pancreatic surgery, the results of the research are still controversial.\textsuperscript{[13–15]} Despite the disputes regarding octreotide, it is very common to use octreotide to prevent complications in many clinical centers. Therefore, we conducted an updated meta-analysis of randomized controlled trials (RCTs) to further evaluate the effectiveness of prophylactic use of octreotide to prevent complications after pancreatic surgery. We hope to provide the present best evidence regarding if prophylactic octreotide is necessary after pancreatic resection.

2. Methods
Ethical approval or patient consent was not required since the present study was a review of previous published literature.

2.1. Search strategy and selection criteria
We identified relevant studies by searching databases including MEDLINE, EMBASE, and the Cochrane Controlled Trial Register on the Cochrane Library from inception to July 2018. The references of the identified studies were also searched to identify further relevant studies. The research was not restricted by language. We used the following terms and keywords: “pancreatoduodenectomy or pylorus-preserving pancreaticoduodenectomy or PD or PPPD or pancreatic resection or pancreatectomy or distal pancreatectomy or DP” and “octreotide or octreotide acetate or somatostatin analogue,” and “randomized controlled trial or RCT or controlled clinical trial or randomized or clinical trials as topic or placebo or randomly or trial.” The inclusion criteria were as follows: the study included all published RCTs that included adults (aged older than 18 years) who underwent surgery involving partial pancreatectomy (surgery for pancreatic cancer, pancreatic-related benign tumors, and cancer-related benign tumors). Records identified through database searching (\(n=2586\))

\[\text{Records after duplicates removed} (n=2379)\]

\[\text{Records screened} (n=2379)\]

\[\text{Records excluded for irrelevant titles or abstracts} (n=2346)\]

\[\text{4 studies were excluded for not about the prevention of postoperative complications}\]

\[\text{4 studies were excluded for multiple reports}\]

\[\text{4 studies were about other irrelevant therapies}\]

\[\text{5 studies were non-randomized}\]

\[\text{3 studies compared somatostatin with octreotide}\]

\[\text{Full-text articles assessed for eligibility} (n=33)\]

\[\text{Studies included in quantitative synthesis (meta-analysis)} (n=13)\]

Figure 1. Flow diagram of studies screening according to PRISMA guidelines. PRISMA=Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
| Author, year | Multi or single center | Patients per group | Mean age | Administration methods | Surgical approach | Pathology | Pancreatic fistula definition |
|-------------|-----------------------|-------------------|----------|------------------------|------------------|----------|-----------------------------|
| El Nakeeb et al, 2018[19] | Single center | Octreotide 52 | 54.4 | 100 μg per 8 h until fluids intake | PD | Malignancy; Chronic pancreatitis; Other tumor | According to the ISGPF |
| | Control 52 | 55.5 | | | | Chronic pancreatitis; Pancreatic fistula definition |
| Kurumboor et al, 2015[20] | Single center | Octreotide 55 | 56±9.2 | 100 μg per 8 h for 5 days | PD | Malignancy; Other tumor | According to the ISGPF |
| | Control 54 | 69 | | | | Chronic pancreatitis; Periampullary |
| Fernandez et al, 2013[21] | Single center | Octreotide 32 | 56±11.6 | 100 μg per 8 h for 10 days | PPPD | Malignancy; Other tumor | According to the ISGPF |
| | Control 30 | 69 | | | | Chronic pancreatitis; NS |
| | | | | | | Chronic pancreatitis; Other tumor |
| Kurumboor et al, 2012[22] | Single center | Octreotide 24 | NS | 100 μg per 8 h for 5 days | PD | NS | NS |
| | Control 21 | 52 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | NS |
| Kollmar et al, 2008[23] | Single center | Octreotide 35 | 59.9±2.0 | 100 μg per 8 h for 10 days | PPPD | Malignancy; Any volume after day 3 with amylase contents >3 times normal serum amylase |
| | Control 32 | 64.8±2.0 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PD |
| Hesse et al, 2005[24] | Single center | Octreotide 55 | 59.9±13.7 | 100 μg per 8 h for 7 days | PD | Cancer; >100 mL/d of amylase-rich fluid >5 times the NSA after day 3 and persisting beyond POD7 with rising temperature and proctitis conditions |
| | Control 50 | 58.9±13.7 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PD |
| Suc et al, 2004[25] | Multicenter | Octreotide 122 | 56±14 | 100 μg per 8 h for 10 days | PD | Malignancy; Any volume after day 3 with amylase contents >3 times normal serum amylase |
| | Control 108 | 57±12 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PPPD |
| | | | | | | PD |
| Yeo et al, 2000[26] | Multicenter | Octreotide 104 | 63.9±1.3 | 100 μg per 8 h for 7 days | PD | Malignancy; >50 mL/d amylase-rich fluid and >3 times normal serum values or after day 10 or radiological pancreatic anastomosis disruption |
| | Control 107 | 65.5±1.1 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PD |
| Lowy et al, 1997[27] | Single center | Octreotide 57 | 63 | 150 μg per 8 h for 5 days | PD | Malignancy; Amylase-rich fluid >2.5 times NSA with fever, leukocytosis, or sepsis or need for percutaneous drainage |
| | Control 53 | 65 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PD |
| Friess et al, 1995[28] | Multicenter | Octreotide 122 | 48 | 100 μg per 8 h for 8 days | PD | PPPD | Amylase and lipase >3 times serum concentration, >3 days postoperative, >10 mL/h |
| | Control 125 | 47 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | DP |
| | | | | | | MRI |
| Montorsi et al, 1995[29] | Multicenter | Octreotide 111 | 59.4±10.8 | 100 μg per 8 h for 7 days | PD | Pancreatic and periampullary cancer; Whipple | >10 mL/d amylase-rich fluid >3 times normal serum amylase since the POD 3 |
| | Control 107 | 56.9±12.5 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PD |
| Pederzoli et al, 1994[30] | Multicenter | Octreotide 122 | 52.6±1.1 | 100 μg per 8 h for 7 days | PD | Pancreatic and periampullary cancer; Chronic pancreatitis; Other tumor | >10 mL/d amylase-rich fluid >3 times normal serum amylase since the POD 4 |
| | Control 130 | 53.6±1.2 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PPPD |
| | | | | | | PD |
| Buchler et al, 1992[31] | Multicenter | Octreotide 125 | 51 | 100 μg per 8 h for 7 days | PD | Pancreatic and periampullary cancer; Chronic pancreatitis; Other tumor | >10 mL/d amylase-rich fluid >3 times normal serum amylase since the POD 4 |
| | Control 121 | 52 | | | | Chronic pancreatitis; Other tumor |
| | | | | | | PPPD |
| | | | | | | PD |

DP = distal pancreatectomy, LR = left resection (left pancreatectomy), NSA = normal serum amylase, PD = pancreaticoduodenectomy, POD = postoperative day, PPPD = pylorus-preserving pancreaticoduodenectomy, SP = subtotal pancreatectomy.
common bile duct cancer, periampullary cancer, chronic pancreatitis, and trauma). Octreotide was administered prophylactically in the intervention group, and placebo or no intervention was used in the control group. The aim of using octreotide prophylaxis was to prevent complications after pancreatic resection. The primary outcome was the incidence of PF after pancreatic surgery. The secondary endpoints included mortality and other postoperative complications.

The exclusion criteria were as follows: patient information that was unclear and studies that compared octreotide with other prophylactic interventions.

2.2. Data extraction

Two reviewers independently identified the trials according to the predesigned protocol. The basic details were extracted including the name of first author, publication year, country, study design, number of patients, mean age, surgical procedure, administration methods of octreotide, definition of PF, complications in each group, primary endpoints including the incidences of PF and clinically significant PF, and secondary endpoints including the incidences of mortality, overall complications, abdominal infection, bleeding, pulmonary complications, reoperation, biliary leakage, and delayed gastric emptying.

2.3. Assessment of quality

Two reviewers independently screened, extracted, and evaluated the relevant information from the articles. Risk of bias in the included studies was assessed by the Cochrane Collaboration tool.[16] The quality of the included studies was evaluated by 7 parameters: random sequence generation, allocation concealment, masking of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. The items were estimated as “low risk,” “unclear risk,” or “high risk.” Any disagreement was resolved by a discussion until a consensus was reached.

2.4. Statistical methods

Meta-analysis was conducted using Review Manager 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark). The pooled risk ratios (RRs) and 95% confidence interval (CIs) were calculated for dichotomous outcomes. The pooled mean difference (MD) or standardized mean difference (SMD) with the 95% CI was estimated for continuous outcomes. Heterogeneity among the studies was investigated with the Q test and I² test with Revman software. If $P < 0.05$ and $I^2 > 50\%$, there was significant heterogeneity; if $P \geq 0.05$ and $I^2 \leq 50\%$, there was no significant heterogeneity. If there was significant heterogeneity, we analyzed data using a random effects model. If there was not significant heterogeneity, we used a fixed effects model.[17,18] A funnel plot was used to explore publication bias. We performed a subgroup analysis based on the level of risk (low-risk stratum vs high-risk stratum) and the surgical procedures (PD vs DP and local pancreatic resection). Pancreas with soft texture and non-dilated pancreatic ducts were considered to belong to the high-risk stratum. A $P$ value $<0.05$ was considered statistically significant.

3. Results

3.1. Description of studies

A total of 2586 records were identified by the search strategy. A total of 207 duplicates and 2346 clearly irrelevant references identified by reading the titles and abstracts were excluded. Thirty-three references were retrieved for further assessment. Of the 33 references, 4 studies were not about the prevention of postoperative complications, 4 studies were multiple reports, 4 studies were about other irrelevant therapies, 5 studies were non-randomized, and 3 studies compared somatostatin with octreotide (Fig. 1). Finally, 13 RCTs were included in the meta-analysis (Table 1).

All of the studies were in English. The meta-analysis involved a total of 2006 patients: 1016 were randomized to the octreotide group, and 990 were randomized to the control group. Seven trials had single-center designs, and 6 trials had multicenter designs. The characteristics of the 13 studies including the different definitions of PF are presented in Table 1.

3.2. Risk of bias within studies

The risk of bias of the included studies is presented in Figs. 2 and 3. Overall, the included studies were sufficiently evaluated as...
having a low risk or moderate risk of bias across the domains. Of the 13 studies, 12 studies provided the details of the generation of the randomization sequence,[19,26–31] and only 1 study used an improper randomization method.[27] Eight studies used a double-blind method,[19,22,23,26–28,31] 4 studies adopted a single-blind or open-label method,[23,24,25,27] and 1 study did not mention the blinding method.[20] There was a low risk of attrition bias due to the low rate of loss of follow-up, making it unlikely to cause significant bias. The “other risk of bias” was reported as unclear in all the studies.

3.3. Results of the meta-analyses
3.3.1. Primary outcomes: PF and clinically significant PF.
There were no differences between the 2 groups in the incidences of PF and clinically significant PF. After pooling all the trials, 414 PFs occurred (414/2006, 20.6%), including 180 in the octreotide group (180/1016, 17.7%) and 234 in the control group (234/990, 23.6%). The pooled RR was 0.79 (95% CI 0.62–0.99, \( P = .05 \)) (Fig. 4). Eighty-eight clinically significant PFs occurred (88/832, 10.6%), including 46 in the octreotide group (46/432, 10.6%) and 42 in the control group (42/400, 10.5%). The pooled RR was 1.01 (95% CI 0.68–1.50, \( P = .95 \)) (Fig. 5).

3.3.2. Secondary outcome: postoperative complications.
There were no significant differences between the 2 groups in the incidences of mortality (RR = 1.21, 95% CI 0.78–1.88, \( P = .40 \)) (Fig. 6), biliary leakage (RR 0.84, 95% CI 0.39–1.82, \( P = .66 \)) (Fig. 7), delayed gastric emptying (RR = 0.83, 95% CI = 0.54–1.27, \( P = .39 \)) (Fig. 8), abdominal infection (RR = 1.00, 95% CI = 0.66–1.52, \( P = .00 \)) (Fig. 9), bleeding (RR = 1.16, 95% CI = 0.78–1.72, \( P = .46 \)) (Fig. 10), pulmonary complications (RR = 0.73, 95% CI = 0.45–1.18, \( P = .20 \)) (Fig. 11), overall complications (RR = 0.80, 95% CI = 0.64–1.01, \( P = .06 \)) (Fig. 12), and reoperation rates (RR = 1.18, 95% CI = 0.77–1.81, \( P = .45 \)) (Fig. 13).

3.4. Subgroup analyses
In subgroup analyses, the included studies stratified patients into 2 groups: high-risk and low-risk groups. The pooled analysis showed that there was no significant difference in the incidence of PF in the high-risk group (RR = 0.81, 95% CI = 0.67–1.00, \( P = .05 \)) and the low-risk group (RR = 0.58, 95% CI = 0.14–2.33, \( P = .45 \)) (Fig. 14). Additionally, there was no significant difference between the PD group (RR = 1.01, 95% CI = 0.83–1.22, \( P = .96 \)) and the DP and local pancreatic resection group (RR = 0.38, 95% CI = 0.14–1.05, \( P = .06 \)) (Fig. 15).

3.5. Publication bias
We assessed the publication bias based on the results of PF and clinically significant PF. No evidence of publication bias existed in the studies included in the meta-analysis (Figs. 16 and 17).

4. Discussion
POPF is the most frequent major complication after pancreatic resection and may lead to secondary intra-abdominal abscess formation and septic and hemorrhagic complications and even death.[32,33] Pancreatic exocrine secretions are considered a major contributor to the development of POPF after pancreatic resection. Thus, inhibition of these secretions may reduce the incidence of POPF after pancreatic resection. Octreotide is known to inhibit exocrine secretions from the pancreas and may reduce the incidence of PF after pancreatic surgery.[34,10] Since 1979, several clinical trials have evaluated the effect of octreotide and attempted to determine whether octreotide can prevent complications after pancreatic resection. However, until now, the results were still quite conflicting.

The purpose of our meta-analysis was to evaluate the efficacy of prophylactic octreotide for the prevention of complications after pancreatic resection. The present evidence suggests that prophylactic octreotide had no effective role in reducing the incidence of complications after pancreatic surgery, including the
**Figure 4.** Forest plot of meta-analysis comparing octreotide with control group in pancreatic fistula.

| Study or Subgroup  | Octreotide Events | Control Events | Weight | Risk Ratio M-H, Random, 95% CI Year |
|--------------------|-------------------|----------------|--------|-----------------------------------|
| Büchner 1992       | 22 125            | 46 121         | 11.2%  | 0.46 [0.30, 0.72] 1992             |
| Pederzoli 1994     | 11 122            | 24 130         | 7.5%   | 0.49 [0.26, 0.98] 1994             |
| Fries 1995         | 12 122            | 28 125         | 8.0%   | 0.44 [0.23, 0.82] 1995             |
| Montorsi 1995      | 10 111            | 21 107         | 7.0%   | 0.48 [0.23, 0.93] 1995             |
| Lowy 1997          | 16 117            | 11 153         | 7.4%   | 1.35 [0.69, 2.24] 1997             |
| Yeo 2000           | 11 104            | 10 107         | 5.8%   | 1.13 [0.50, 2.55] 2000             |
| Suc 2004           | 21 122            | 20 108         | 9.2%   | 0.93 [0.53, 1.62] 2004             |
| Hesse 2005         | 5 55              | 4 50           | 3.0%   | 1.14 [0.32, 4.00] 2005             |
| Kollmar 2008       | 9 35              | 6 32           | 4.9%   | 1.37 [0.55, 3.42] 2008             |
| Kurumburco 2012    | 18 24             | 16 21          | 13.6%  | 0.98 [0.71, 1.37] 2012             |
| Fernandez 2013     | 2 32              | 3 30           | 1.7%   | 0.63 [0.11, 3.48] 2013             |
| Kurumburco 2015    | 33 55             | 34 54          | 14.3%  | 0.95 [0.71, 1.28] 2015             |
| Nakeeb 2018        | 10 52             | 11 52          | 6.3%   | 0.91 [0.42, 1.95] 2018             |

Total (95% CI) 1016 990 100.0% 0.79 [0.62, 0.99]

**Figure 5.** Forest plot of meta-analysis comparing octreotide with control group in clinically significant pancreatic fistula.

| Study or Subgroup  | Octreotide Events | Control Events | Weight | Risk Ratio M-H, Fixed, 95% CI Year |
|--------------------|-------------------|----------------|--------|-----------------------------------|
| Lowy 1997          | 7 57              | 3 53           | 7.1%   | 2.17 [0.59, 7.96] 1997             |
| Suc 2004           | 13 122            | 9 108          | 21.9%  | 1.28 [0.57, 2.87] 2004             |
| Hesse 2005         | 5 55              | 4 50           | 9.6%   | 1.14 [0.32, 4.00] 2005             |
| Kollmar 2008       | 5 35              | 4 32           | 9.6%   | 1.14 [0.34, 3.89] 2008             |
| Kurumburco 2012    | 4 24              | 5 21           | 12.2%  | 0.70 [0.22, 2.27] 2012             |
| Fernandez 2013     | 2 32              | 3 30           | 7.1%   | 0.63 [0.11, 3.48] 2013             |
| Kurumburco 2015    | 6 55              | 10 54          | 23.2%  | 0.59 [0.23, 1.51] 2015             |
| Nakeeb 2018        | 4 52              | 4 52           | 9.2%   | 1.00 [0.26, 3.79] 2018             |

Total (95% CI) 432 400 100.0% 1.01 [0.68, 1.50]

**Figure 6.** Forest plot of meta-analysis comparing octreotide with control group in mortality.

| Study or Subgroup  | Octreotide Events | Control Events | Weight | Risk Ratio M-H, Fixed, 95% CI Year |
|--------------------|-------------------|----------------|--------|-----------------------------------|
| Büchner 1992       | 4 125             | 7 121          | 20.6%  | 0.55 [0.17, 1.84] 1992             |
| Pederzoli 1994     | 2 122             | 5 130          | 14.2%  | 0.43 [0.08, 2.16] 1994             |
| Montorsi 1995      | 9 111             | 6 107          | 17.9%  | 1.45 [0.53, 3.92] 1995             |
| Fries 1995         | 2 122             | 1 125          | 2.9%   | 2.05 [0.19, 22.31] 1995             |
| Lowy 1997          | 1 57              | 0 53           | 1.5%   | 2.79 [0.12, 67.10] 1997             |
| Yeo 2000           | 1 104             | 0 107          | 1.4%   | 3.09 [0.13, 74.90] 2000             |
| Suc 2004           | 15 122            | 8 108          | 24.9%  | 1.68 [0.73, 3.76] 2004             |
| Hesse 2005         | 1 55              | 0 50           | 1.5%   | 2.73 [0.11, 65.57] 2005             |
| Kollmar 2008       | 2 35              | 1 32           | 3.1%   | 1.83 [0.17, 19.21] 2008             |
| Fernandez 2013     | 0 32              | 0 30           | Not estimable | 2013 |
| Kurumburco 2015    | 1 55              | 1 54           | 3.0%   | 0.98 [0.06, 15.30] 2015             |
| Nakeeb 2018        | 3 52              | 3 52           | 8.8%   | 1.00 [0.21, 4.73] 2018             |

Total (95% CI) 992 969 100.0% 1.21 [0.78, 1.88]
Figure 7. Forest plot of meta-analysis comparing octreotide with control group in biliary leakage.

Figure 8. Forest plot of meta-analysis comparing octreotide with control group in delayed gastric emptying.

Figure 9. Forest plot of meta-analysis comparing octreotide with control group in abdominal infection.

Figure 10. Forest plot of meta-analysis comparing octreotide with control group in bleeding.
incidence of PF. The results were different from those of previous meta-analyses\cite{35-37} that showed that the prophylactic use of octreotide could significantly reduce the incidence of some complications, especially PF. Some previous studies recommended the prophylactic use of octreotide.

Because of these different results, there are many things that need to be further discussed. First, the studies included in our meta-analysis did not use the same standard definitions of PF. In 2005, the definition of PF achieved uniformity, and POPF was graded as A, B, and C. Grade A fistulas are transient and have no clinical importance. Grade B and C fistulas have significant clinical impact, require changes in treatment and may cause an increase in morbidity and mortality.\cite{38} In 2016, the International Study Group for Pancreatic Surgery (ISGPS) redefined Grade A PF to no longer be a true PF.\cite{39} In our study, only 3 trials used the International Study Group for Pancreatic Fistula (ISGPF) definition,\cite{19-21} and other trials used their own definitions of PF. Therefore, potential clinical heterogeneity could not be absolutely excluded. Furthermore, lack of high-quality RCTs, different surgery procedure and experience, different preopera-
Figure 14. Forest plot of meta-analysis comparing octreotide with control group with the risk factor with pancreatic fistula.

Figure 15. Forest plot of meta-analysis comparing octreotide with control group with the surgical procedures with pancreatic fistula following pancreatic resection.
tive nutritional status, and other reasons may also cause potential clinical heterogeneity. Second, soft texture and a non-dilated pancreatic duct are independent risk factors for POPF. The study by Callery et al reported that patients with ampullary, duodenal, cystic, or islet cell pathology are more likely to develop POPF than patients with pancreatic cancer or chronic pancreatitis. An explanation may be the soft pancreatic texture and non-dilated pancreatic duct in pancreases with ampullary, duodenal, cystic, or islet cell pathology. Some studies have classified postoperative patients into high-risk and low-risk groups based on the pathology of the disease, texture of the pancreas, and diameter of the pancreatic duct. These studies have shown that the prophylactic use of octreotide might decrease the incidence of PF in high-risk patients. However, in our study, the meta-analysis of the subgroup high-risk patients showed that octreotide could not decrease the incidence of PF in these high-risk patients. Therefore, we believe that the prophylactic use of octreotide for high-risk patients should not be recommended. Third, the clinical trials included many types of pancreatic resections. There is a significantly different incidence of POPF between different types of pancreatic surgery procedures (such as PD and DP). The study by Montorsi et al reported that the prophylactic use of octreotide could reduce the occurrence of PF in patients who underwent DP but not in patients who underwent...
PD. However, the study by Suc et al.\(^22\) reported the different results, which revealed that octreotide could be useful in patients who underwent PD by pancreateojunostomy and had a high risk of PF (a main pancreatic duct measuring <3 mm) but not in those who underwent DP. In our study, the meta-analysis of subgroup of different surgery methods showed that octreotide could not reduce the rate of PF after DP and local pancreatic resection. Therefore, additional high-quality RCTs to evaluate the efficacy of octreotide to prevent postoperative complications after DP and local pancreatic resection are needed. Fourth, different methods of anastomosis (such as pancreateojunostomy and pancreateogastrostomy) may cause different rates of PF. Because pancreatic enzymes cannot activate in gastric tissue, the use of octreotide may be useless after pancreateogastrostomy. If octreotide can reduce the rate of PF after surgery, the reason for this effect may not be that octreotide reduces pancreatic enzyme secretion. A study by Suc et al.\(^22\) reported that the prophylactic use of octreotide can reduce the incidence of intra-abdominal complications after pancreateojunostomy but cannot reduce the incidence of intra-abdominal complications after pancreateogastrostomy. However, this article did not further analyze the reason why octreotide reduces the incidence of complications between these 2 methods of anastomosis. Therefore, more RCTs with a greater number of patients and using the ISGSP standard PF definition and standard surgical procedures are needed to evaluate the efficacy of octreotide in different methods of anastomosis. Last but not least, the adverse effects of octreotide are worth consideration. The prophylactic use of octreotide may result in prolonged recovery time of the intestine and increase delayed gastric emptying due to decreased secretion of digestive enzymes.\(^4\)\(^5\)\(^6\) Some studies have also revealed that octreotide can inhibit the anabolism of the body and suppress the secretion of tropic hormones, which may delay the healing of each anastomosis.\(^4\)\(^5\)\(^6\) A study by Jenkins et al.\(^7\) showed that octreotide can decrease the volume of pancreatic juice. However, a low volume of pancreatic juice may cause a high concentration of enzymes, which may delay the healing of anastomosis sites. However, in our meta-analysis, prophylactic octreotide did not significantly prolong gastric emptying after pancreatic resection and cause other serious adverse effects. The adverse effects of octreotide were mainly minor and well tolerated. The reason for the results of this meta-analysis may be that although octreotide can reduce pancreatic exocrine secretions, octreotide can also shrink the visceral vessels and decrease gastrointestinal blood flow, which reduces the blood supply to the pancreaticointestinal anastomosis and can also reduce the secretion of growth hormone (GH).\(^11\)\(^3\)\(^4\) These factors are not helpful for the healing of the anastomosis site and may cause other complications.

5. Conclusion

The best available evidence showed that octreotide had no influence on the incidence of PF and other complications after pancreatic resection. The prophylactic use of octreotide is not recommended. However, further high-quality RCTs to assess which subgroup of patients may benefit from prophylactic octreotide administration are urgently needed.

Author contributions

Conceptualization: Qiang Huang.
Data curation: Hao Zheng, Jiwei Qin.

Formal analysis: Hao Zheng, Jiwei Qin, Ning Wang.
Investigation: Hao Zheng.
Methodology: Hao Zheng, Wanjing Chen.
Project administration: Qiang Huang.
Software: Hao Zheng, Jiwei Qin, Ning Wang, Wanjing Chen.
Supervision: Qiang Huang.
Validation: Qiang Huang.
Writing – original draft: Hao Zheng, Jiwei Qin.
Writing – review & editing: Hao Zheng, Jiwei Qin.

References

[1] Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet 2016;388:73–85.
[2] Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreatoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786–95.
[3] Yeo CJ, Cameron JL, Soin TA, et al. Six hundred fifty consecutive pancreatoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248–60.
[4] Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection: the importance of definitions. Dig Surg 2004;21:34–9.
[5] Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty five consecutive pancreatoduodenectomies without mortality. Ann Surg 1993;217:430–5. discussion 435–8.
[6] Trede M, Schwall G. The complications of pancreatostomy. Ann Surg 1988;207:39–47.
[7] Kemmer TP, Malfertheniner P, Buchler M, et al. Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide. Aliment Pharmacol Ther 1992;6:41–50.
[8] Petrin P, Antoniutti M, Zaramella D, et al. Effect of octreotide acetate on pancreatic exocrine and endocrine functions after pancreateoduodenal resection. Eur Surg Res 1995;27:371–8.
[9] Poon RT, Fan ST. Decreasing the pancreatic leak rate after pancreatoduodenectomy. Adv Surg 2008;42:33–48.
[10] Klempa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg 1979;50:427–31.
[11] Kohler E, Beglinger C, Dettwiler S, et al. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1986;2:154–9.
[12] Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133–40.
[13] McMillan MT, Christein JD, Callery MP, et al. Prophylactic octreotide for pancreatoduodenectomy: more harm than good? HPB (Oxford) 2014;16:954–62.
[14] Gans SL, van Westreenen HL, Kiewiet JJ, et al. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. Br J Surg 2012;99:754–60.
[15] Drymousis P, Pat M, Spalding D, et al. Is octreotide beneficial in patients undergoing pancreatoduodenectomy? Best evidence topic (BET). Int J Surg 2013;11:779–82.
[16] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[17] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
[18] Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987;6:341–50.
[19] El Nakheb A, ElGawaly A, Ali AM, et al. Efficacy of octreotide in the prevention of complications after pancreatoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: a prospective randomized trial. Hepatobiliary Pancreat Dis Int 2018;17:59–63.
[20] Kurumboor P, Palaniswami KN, Pramul K, et al. Octreotide does not prevent pancreatic fistula following pancreatoduodenectomy in patients with soft pancreas and non-dilated duct: a prospective randomized controlled trial. J Gastrointest Surg 2015;19:2038–44.
[21] Fernandez-Cruz L, Jimenez CE, Taura P, et al. Prospective randomized trial of the effect of octreotide on pancreatic juice output after pancreatoduodenectomy in relation to histological diagnosis, duct size and leakage. HPB (Oxford) 2013;15:392–9.
[22] Kurumboor P, Kamalesh NP, Pramil K, et al. A prospective randomized controlled trial on use of octreotide in patients with acute pancreatitis undergoing pancreaticoduodenectomy: interim analysis. HPB (Oxford) 2012;14:225.

[23] Kollmar O, Mousaviani MR, Richter S, et al. Prospective study of prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blind placebo-controlled trial. Eur J Surg Oncol 2008;34:868–75.

[24] Reiner F, DeDecker C, Houtmeyers P, et al. Prospective randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreateo-duodenectomy. World J Surg 2005;29:1325–38.

[25] Su B, Msika S, Piccinini M, et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Arch Surg 2004;139:288–94.

[26] Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419–29.

[27] Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of prophylactic octreotide and general complications after pancreatic surgery and pancreateo-duodenectomy. World J Surg 2005;29:1325–38.

[28] Friess H, Beger HG, Sulkowski U, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 1995;82:1270–3.

[29] Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995;117:26–31.

[30] Pederzoli P, Bassi C, Falconi M, et al. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Br J Surg 1994;81:263–9.

[31] Büchler M, Friess H, Klöppel I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Ann Surg 1992;162:125–30.

[32] Büchler M, Daskalaki D, Molinari E, et al. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg 2008;15:247–51.

[33] Anderson RJ, Dunki-Jacobs E, Callender GG, et al. Clinical evaluation of somatostatin use in pancreatic resections: clinical efficacy or limited benefit? Surgery 2013;154:755–60.

[34] Heintges T, Lüthen R, Niederau C. Inhibition of exocrine pancreatic secretion by somatostatin and its analogues. Digestion 1994;55 (suppl):1–9.

[35] Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can J Surg 2007;50:459–66.

[36] Kori RS, Gurusamy KS, Fusi G, et al. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 2010;12:155–65.

[37] Wang CL, Zhao X, You SY. Efficacy of the prophylactic use of octreotide for the prevention of complications after pancreatic resection: an updated systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017;96:e7500.

[38] Bassi C, Derwich C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8–13.

[39] Bassi C, Marchegiani G, Derwich C, et al. The 2016 update of the International Study Group (ISGPF) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2017;161:584–91.

[40] Murakami Y, Uemura K, Hayasidani Y, et al. A soft pancreatic remnant is associated with increased drain fluid pancreatic amylase and serum CRP levels following pancreateoduodenectomy. J Gastrointest Surg 2008;12:51–6.

[41] Callery MP, Pratt WB, Kent TS, et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreateoduodenectomy. J Am Coll Surg 2012;214:1–4.

[42] Pratt W, Mathel SK, Vanouou T, et al. Postoperative pancreatic fistulas are not equivalent after proximal, distal, and central pancreatectomy. J Gastrointest Surg 2006;10:1264–78.

[43] Turkcapar AG, Demirer S, Sengul N, et al. The adverse effects of octreotide on wound healing. Eur J Gastroenterol Hepatol 2004;16:475–8.

[44] Shan YS, Sy ED, Tsai ML, et al. Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin. World J Surg 2005;29:1319–24.

[45] Konturek SJ, Dembinski A, Warzecha Z, et al. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 1988;94:1300–7.

[46] Yildiz S, Uluoruk H, Gunay A, et al. The effect of hyperbaric oxygen therapy on the adverse effects of octreotide on wound healing. Eur J Gastroenterol Hepatol 2004;16:475–8.

[47] Jenkins SA, Nott DM, Baxter JN. Fluctuations in the secretion of pancreatic enzymes between consecutive doses of octreotide: implications for the management of fistulae. Eur J Gastroenterol Hepatol 1995;7:255–8.